Replies to post #217250 on Biotech Values

[DewDiligence]

MNTA 4Q17 results /2018 guidance:

http://ir.momentapharma.com/news-releases/news-release-details/momenta-pharmaceuticals-reports-fourth-quarter-and-year-end-2017

Guidance for 2018 gross operating expenses is $180-220M ($45-55M per quarter). Some of this amount will, of course, be offset by royalties and collaborative R&D revenue.

At 12/31/17, MNTA had $397.9M of cash.